A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma
Clinical Cancer Research2016Vol. 22(19), pp. 4776–4785
Citations Over TimeTop 10% of 2016 papers
R. Rampling, Sharon Peoples, Paul Mulholland, Allan James, Omar Al‐Salihi, Christopher Twelves, Catherine McBain, Sarah Jefferies, Alan Jackson, William Stewart, Juha Lindner, Sarah Kutscher, Norbert Hilf, Lesley McGuigan, Jane Peters, Karen A. Hill, Oliver Schoor, Harpreet Singh‐Jasuja, Sarah Halford, James W.A. Ritchie
Abstract
IMA950 plus GM-CSF was well-tolerated with the primary immunogenicity endpoint of observing multi-TUMAP responses in at least 30% of patients exceeded. Further development of IMA950 is encouraged. Clin Cancer Res; 22(19); 4776-85. ©2016 AACRSee related commentary by Lowenstein and Castro, p. 4760.
Related Papers
- → Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines(2014)47 cited
- → The role of temozolomide in newly-diagnosed glioblastoma multiforme(2008)
- → Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme(2006)
- → 42 A novel approach using accelerated hypo-fractionation-IMRT (AH-IMRT) and temozolomide (TMZ) in patients with glioblastoma multiforme (GBM)(2006)
- 2. Glioblastoma再発に対しTemozolomideを使用した１例(第35回群馬脳腫瘍研究会)(2009)